OBJECTIVES To analyse HTA recommendations for cancer drug technologies issued by Agency for Health Technology Assessment (AHTAPol) in Poland and to verify if official threshold value for cost-effectiveness is respected. METHODS The review of  HTA recommendations concerning cancer technologies issued by AHTAPol  in the period from January 2012 to March 2014 was preformed. The classification of HTA recommendations based on Raftery’s approach labeling them as positive, positive with major or minor restriction and negative was conducted. Decisions and ICURs values from each recommendation were compared to the official threshold value for cost-effectiveness (in Poland defined as 3xGDP for each year) and defined whether the ICUR value is either above or below the official threshold. Other aspects of recommendations, such as criterion for decision, type of RSS implemented and reasons for restrictions were also analysed. RESULTS In the studied period AHTAPol issued 46 recommendations for 35 different cancer drugs (due to the multiplied recommendations for 4 drugs). After review, 32 recommendations with calculated ICUR (with Risk Sharing Scheme (RSS) if implemented) were included in the analysis. For 11 of 13 negative recommendations ICUR values were placed above official AHTAPol’s threshold. For 7 of 11 positive recommendations ICUR values were placed below threshold. On the other hand, for 5 of 7 positive recommendations with major restriction ICUR values were placed above official threshold. However, restrictions were related to the unacceptable cost-effectiveness. The same analysis for the ICUR values without implementation of RSS was conducted to compare the results. CONCLUSIONS The official threshold values set in AHTAPol are respected in the majority of decisions for cancer drugs. Cost-effectiveness is one of the most important criterion of decisions made by AHTAPol. Clinical effectiveness, safety and specificity of end-of-life extending medicines were also considered.